Alvotech Earnings Call: Growth Momentum Meets FDA Risk

Alvotech ((ALVO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Alvotech’s latest earnings call balanced solid commercial momentum with stark regulatory and balance‑sheet risks. Management highlighted robust revenue and EBITDA growth, expanding partnerships, and a deep biosimilar pipeline, but the tone was tempered by U.S. regulatory setbacks, pressure on product margins, volatile cash flows, and elevated leverage that together raise near‑term execution risk.

Top-line and EBITDA Growth

Alvotech reported 2025 revenues of $593 million, up about 21% year over year, as its biosimilar portfolio and partner network continued to scale globally. Adjusted EBITDA climbed 27% to $137 million, implying a 23% margin and underscoring the earnings power from licensing income and operating leverage in the model.

Q4 Performance and Margin Strength

Fourth‑quarter 2025 revenue rose 13% to $173 million, with licensing fees contributing roughly 75% of the total and driving a quarterly gross margin of 66%. Adjusted EBITDA reached $69 million in Q4, a 40% margin that showcased the profitability of the licensing‑heavy mix despite weakness in product sales.

Licensing-Driven Profitability and Revenue Mix

For the full year, revenue split was roughly even between product and licensing, but milestones and licensing fees materially lifted profitability, pushing the 2025 gross margin to around 61%. This high‑margin mix helped deliver improved EBITDA and, notably, Alvotech’s first positive full‑year operating cash flow, even as underlying product economics remain under pressure.

Improved Liquidity and Capital Raised

The company shored up its balance sheet in 2025, raising nearly $300 million through capital markets, including $108 million in convertible bonds and a $100 million senior term loan. Year‑end cash climbed to $172 million, and a new Nasdaq Stockholm listing broadened its investor base and visibility among European equity investors.

Large, Advancing Pipeline

Management emphasized a pipeline of roughly 30 biosimilars aimed at high‑value therapeutic areas and large reference products, positioning Alvotech for long‑term growth. Highlights included positive pivotal pharmacokinetic data for its Entyvio biosimilar, a Keytruda collaboration aiming for a 2028 marketing application, and an Eylea HD candidate targeting first filings in 2026.

Commercial Launches and Geographic Expansion

Beyond the U.S., Alvotech and its partners notched multiple approvals and launches across Europe, the U.K., Japan and other markets during 2025 and early 2026. Key moves included Teva’s U.S. launch of Selarsdi, and European and Japanese approvals for AVT03, AVT05 and AVT06, with AVT05 becoming the first Simponi biosimilar in both Europe and Japan.

Market Share Traction

The company reported solid share gains in key biosimilar segments, suggesting its products are competing effectively on value and supply. Simlandi captured about 9% of the U.S. Humira market and is one of the fastest‑growing biosimilars in that franchise, while Uzpruvo has already secured more than 20% share in the European Stelara biosimilar segment.

Platform and Capability Strengthening

Alvotech is investing in its platform with targeted acquisitions and capacity builds to support multiple global launches. The purchase of Xbrane’s R&D team and the Ivers‑Lee assembly and packaging unit, alongside expansions in Iceland and Stockholm, are designed to scale R&D throughput and downstream manufacturing capacity.

Operational Actions on Regulatory Observations

Following FDA inspection observations at its Reykjavik facility, the company rolled out a comprehensive remediation and quality improvement plan, with most corrective actions completed by year‑end. The site remains FDA‑approved for on‑market products, and Alvotech aims to resubmit the impacted biologics license applications in the first half of 2026 once it can demonstrate sustained compliance.

FDA Letters for U.S. BLAs

Regulatory risk remains front and center after Alvotech received complete response letters and a post‑application action letter for four U.S. biosimilar filings, including Simponi, Simponi Aria, Prolia/Xgeva and Eylea. These setbacks, rooted in the Reykjavik inspection findings, require resubmissions and potentially another FDA inspection, delaying U.S. revenue and adding timing uncertainty.

Soft Product Sales and Negative Product Margin

While licensing shone, product revenues softened in the second half of 2025, particularly in the fourth quarter when product sales totaled $43 million. That quarter also saw a negative product margin of 37%, which management attributed to timing of partner orders, planned facility upgrades and lower manufacturing throughput, underscoring the sensitivity of product economics.

Quarterly Cash Flow Volatility

Operating cash flow turned negative $28 million in Q4 despite a positive $7 million for the full year, reflecting swings in working capital and investment. Inventory increased by roughly $92 million year over year and capital expenditures were elevated, contributing to quarter‑to‑quarter volatility that investors will need to factor into liquidity expectations.

High Leverage and Increased Borrowings

Debt levels climbed following Q4 financing, even as reported net debt to adjusted EBITDA improved to about 9.3 times on stronger earnings. The higher absolute borrowings, fair value movements in derivatives and earn‑outs, and net interest payments of $35 million in Q4 collectively raise financial complexity and heighten sensitivity to execution and interest‑rate conditions.

Deferred Tax and Balance Sheet Adjustments

The company reduced its deferred tax asset by $130 million over 2025, reflecting balance sheet re‑assessments that limit future tax cushions. At the same time, non‑current assets increased 19% and trade receivables declined by about $70 million, underlining a balance sheet in transition as Alvotech invests heavily while tightening working capital.

Operational Dependence and Dual-Sourcing Plans

Management acknowledged that historic dependence on the Reykjavik facility exposed the company to operational and regulatory concentration risks. In response, Alvotech is pursuing dual‑sourcing and U.S. contract manufacturing partnerships to diversify production, aiming to improve supply resilience and reduce the impact of any single‑site disruption.

Revenue Lumpiness and Timing Risk

The heavy reliance on licensing milestones and partner shipments is making both revenue and margins lumpy, with Q4 and full‑year growth significantly driven by such timing‑dependent items. Management cautioned that tenders, milestone triggers and partner order patterns will continue to introduce quarter‑to‑quarter unpredictability even as the underlying business scales.

Forward-Looking Guidance and Outlook

Alvotech reaffirmed 2026 guidance for $650 million to $700 million in revenue and $180 million to $220 million in adjusted EBITDA, with the low end assuming no U.S. launches and performance skewed toward Q4. The company targets positive operating cash flow by year‑end 2026 and expects to resubmit key U.S. filings in the second quarter, aiming for regulatory decisions before year‑end, which could provide upside if approvals land.

Alvotech’s earnings call painted a picture of a company with strong biosimilar momentum and a deep pipeline, but facing meaningful regulatory, margin and leverage challenges. For investors, the story hinges on execution of quality remediation, diversification of manufacturing, stabilization of product margins and the timing of U.S. approvals that could unlock the next leg of growth.